Interim Report January – September 2007 Tripep AB (publ.)

• Research and development costs amounted to SEK 13.3 million
• The loss after tax was SEK -21.7 million
• Earnings per share were SEK -0.45
• The company had no net sales for the period
• Tripep has received all requisite permits for starting a clinical study of ChronVac-C® on patients with chronic Hepatitis C virus infection. The study is scheduled to start in October 2007
• The research on the combination of ChronVac-C® and Inovio’s DNA Delivery System (DDS) technology was presented at the 14th International Symposium on Hepatitis C Virus & Related Viruses in Glasgow on 9-13 September 2007

Events after the end of the reporting period
• After the end of the reporting period, Tripep announced that it had signed a Letter of Intent with Inovio Inc. of San Diego regarding the joint development of ChronVac-B, a therapeutic vaccine against chronic Hepatitis B viral infection



For more information, please contact:

Jan Nilsson, CEO, Tripep AB
Tel: +46 8 449 84 80, mobile phone: +46 70 466 31 63
E-mail: jan.nilsson@tripep.se

Anders Vahlne, Head of Research, Tripep AB
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@ki.se